These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1526 related articles for article (PubMed ID: 17140163)

  • 1. The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease.
    Pennell P; Leclercq B; Delahunty MI; Walters BA
    Clin Nephrol; 2006 Nov; 66(5):336-47. PubMed ID: 17140163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonfasting non-high-density lipoprotein cholesterol is adequate for lipid management in hemodialysis patients.
    Desmeules S; Arcand-Bossé JF; Bergeron J; Douville P; Agharazii M
    Am J Kidney Dis; 2005 Jun; 45(6):1067-72. PubMed ID: 15957136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis.
    Shoji T; Nishizawa Y; Kawagishi T; Tanaka M; Kawasaki K; Tabata T; Inoue T; Morii H
    Atherosclerosis; 1997 Jun; 131(2):229-36. PubMed ID: 9199276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statins for treatment of dyslipidemia in chronic kidney disease.
    Shurraw S; Tonelli M
    Perit Dial Int; 2006; 26(5):523-39. PubMed ID: 16973506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006.
    Tóth PP; Potter D; Ming EE
    J Clin Lipidol; 2012; 6(4):325-30. PubMed ID: 22836069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid Metabolism in Patients with End-Stage Renal Disease: A Five Year Follow-up Study.
    Dusejovska M; Stankova B; Vecka M; Rychlíkova J; Mokrejsova M; Rychlík I; Zak A
    Curr Vasc Pharmacol; 2018; 16(3):298-305. PubMed ID: 28554308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atherogenic lipoproteins in end-stage renal disease.
    Shoji T; Ishimura E; Inaba M; Tabata T; Nishizawa Y
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S30-3. PubMed ID: 11576918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety and tolerability of atorvastatin in dyslipidemic subjects with advanced (non-nephrotic) and endstage chronic renal failure.
    Saltissi D; Westhuyzen J; Morgan C; Healy H
    Clin Exp Nephrol; 2006 Sep; 10(3):201-9. PubMed ID: 17009078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Novel Low-Density Lipoprotein-Cholesterol Assessment on the Utility of Secondary Non-High-Density Lipoprotein-C and Apolipoprotein B Targets in Selected Worldwide Dyslipidemia Guidelines.
    Sathiyakumar V; Park J; Quispe R; Elshazly MB; Michos ED; Banach M; Toth PP; Whelton SP; Blumenthal RS; Jones SR; Martin SS
    Circulation; 2018 Jul; 138(3):244-254. PubMed ID: 29506984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.
    Marrs JC; Saseen JJ
    Pharmacotherapy; 2010 Aug; 30(8):823-9. PubMed ID: 20653359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma lipoprotein abnormalities in hemodialysis patients--clinical implications and therapeutic guidelines.
    Shoji T; Nishizawa Y
    Ther Apher Dial; 2006 Aug; 10(4):305-15. PubMed ID: 16911182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of non-high-density lipoprotein cholesterol in hemodialyzed patients.
    Schreier L; González AI; Elbert A; Berg G; Wikinski R
    Metabolism; 2004 Aug; 53(8):1013-5. PubMed ID: 15281010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease.
    Nishizawa Y; Shoji T; Kakiya R; Tsujimoto Y; Tabata T; Ishimura E; Nakatani T; Miki T; Inaba M
    Kidney Int Suppl; 2003 May; (84):S117-20. PubMed ID: 12694324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathophysiology of Diabetic Dyslipidemia.
    Hirano T
    J Atheroscler Thromb; 2018 Sep; 25(9):771-782. PubMed ID: 29998913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients.
    Kronenberg F; Lingenhel A; Neyer U; Lhotta K; König P; Auinger M; Wiesholzer M; Andersson H; Dieplinger H
    Kidney Int Suppl; 2003 May; (84):S113-6. PubMed ID: 12694323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 77.